The multivalent design approach has been used in a number of other instances, namely with a trivalent “lactose” analog against Gal-4 (Kd of 22 × 10−6 M) [117], a bilactosylated steroid-based compound against Gal-1 [118], and lactulose amine compounds (i.e., polymethylene-spaced dilactoseamine derivatives) that show some selective effects linked to tumor cell apoptosis, cell aggregation, and endothelial cell morphogenesis [119]. The gene discussed is LGALS1; the disease is neoplasm.